{"id":163043,"date":"2019-07-31T11:18:05","date_gmt":"2019-07-31T11:18:05","guid":{"rendered":"http:\/\/www.georgianewsdesk.com\/news\/story\/163043\/cancer-immunotherapy-drug-discovery-outsourcing-market-segmented-on-the-basis-of-drug-type-service-typecancer-type-region-and-forecast-to-2025-grand-view-research-inc.html"},"modified":"2019-07-31T11:18:05","modified_gmt":"2019-07-31T11:18:05","slug":"cancer-immunotherapy-drug-discovery-outsourcing-market-segmented-on-the-basis-of-drug-type-service-typecancer-type-region-and-forecast-to-2025-grand-view-research-inc","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/163043\/cancer-immunotherapy-drug-discovery-outsourcing-market-segmented-on-the-basis-of-drug-type-service-typecancer-type-region-and-forecast-to-2025-grand-view-research-inc.html","title":{"rendered":"Cancer Immunotherapy Drug Discovery Outsourcing Market Segmented On The Basis Of Drug Type, Service Type,Cancer Type, Region And Forecast To 2025 : Grand View Research Inc."},"content":{"rendered":"
\"Cancer<\/a><\/p>\n
\n
Grand View Research, Inc. – Market Research And Consulting.<\/div>\n<\/div>\n<\/div>\n
According to report published by Grand View Research, The global cancer immunotherapy drug discovery outsourcingmarket size was valued at USD 617.6 million in 2017. It is poised to register a CAGR of 13.5% during the forecast period.<\/div>\n

The global <\/a>cancer immunotherapy drug discovery outsourcing market<\/a> <\/strong>size<\/strong> is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.<\/p>\n

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.<\/p>\n

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.<\/p>\n

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment<\/p>\n

\"China<\/p>\n

Request a sample Copy of the Cancer Immunotherapy Drug Discovery Outsourcing Market Research Report @ https:\/\/www.grandviewresearch.com\/industry-analysis\/cancer-immunotherapy-drug-discovery-outsourcing-market\/request\/rs1<\/a><\/strong><\/p>\n

Key Takeways Of The Report :<\/strong><\/p>\n